NCT04816682 (SILCOVINT-21) is a Phase 4 clinical trial of Silymarin in Covid19, sponsored by F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica.

Who is sponsoring NCT04816682?

NCT04816682 is sponsored by F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica.

What drugs are being tested in NCT04816682?

Interventions in NCT04816682: Silymarin.

What condition does NCT04816682 study?

NCT04816682 studies Covid19, Liver Diseases.

Is NCT04816682 still recruiting?

NCT04816682 is currently completed. Last updated 3 August 2022.

Last reviewed 2022-08-03 · How we verify

NCT04816682: SILCOVINT-21

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes

Completed Phase 4 Last updated 3 August 2022

What this trial tests

Phase 4 trial testing Silymarin in Covid19 in 30 participants. Completed in 30 December 2021.

Timeline

17 March 2021

Primary endpoint
30 June 2021

30 December 2021

Quick facts

Lead sponsor	F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	17 March 2021
Primary completion	30 June 2021
Estimated completion	30 December 2021
Sites	2 locations across Slovakia

Drugs / interventions tested

Silymarin — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
Liver Diseases — all drugs for Liver Diseases →

Sponsor

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

Who can join

19 and older, any sex, with Covid19 or Liver Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Of patients admitted to an internal medicine ward with internistic diagnosis/es together with COVID-19, substantial proportion has elevated liver enzymes. silymarin / silibinin (milk thistle extract) has been approved as an add-on therapy in various acute and chronic liver diseases; moreover, there is evidence to suggest that it's dual effect (anti-viral and immune-modulatory) might be of benefit in patients infected with SARS-CoV-2. As there is no effective/approved pharmacotherapy for COVID-19, a pilot study with Silymarine in hospitalised patients has been undertaken

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Small molecules in the treatment of COVID-19.
Lei S, Chen X, Wu J, Duan X, et al · · 2022 · cited 74× · PMID 36464706 · DOI 10.1038/s41392-022-01249-8
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin.
Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, et al · · 2021 · cited 5× · PMID 35056076 · DOI 10.3390/ph15010019
FAAH Modulators from Natural Sources: A Collection of New Potential Drugs.
Nicoara C, Fezza F, Maccarrone M. · · 2025 · cited 4× · PMID 40214504 · DOI 10.3390/cells14070551
Impact of COVID-19 on Nonpulmonary Critical Illness: Prevalence, Clinical Manifestations, Management, and Outcomes.
Pirzadeh M, Prescott HC. · · 2023 · PMID 37085218 · DOI 10.1016/j.ccm.2022.11.011

Verify or expand the search:

Other trials of Silymarin

Trials testing the same drug.

NCT06922669 — Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia · NA · recruiting
NCT07123922 — Effect of Silymarin as Add on Therapy on Oxidative Stress, Pulmonary Function and Quality of Life in Stable COPD Patient · NA · enrolling by invitation
NCT07001150 — Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease · Phase 2 · recruiting
NCT06114719 — Silymarin for the Prevention of Atrial Fibrillation After Cardiac Surgery · Phase 3 · completed
NCT05595109 — Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients · Phase 2, PHASE3 · unknown

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica trials

Trials by the same sponsor.

NCT07439913 — Predictive Factors for 10-year Biochemical Recurrence and Urinary Continence Following Robot-assisted Radical Prostatect · enrolling by invitation
NCT05156008 — Comparison of Ultrasound-guided and Palpation-inserted Peripheral Venous Cannula · NA · unknown
NCT05486767 — Screening of Liver Fibrosis in Adults Without Known Liver Disease · unknown
NCT04758806 — Fecal Microbial Transplantation in Severe Alcoholic Hepatitis · Phase 3 · unknown
NCT05261165 — Effect of a Uterine Manipulator on the Incidence of Lymphovascular Propagation (LVSI) in Treatment of Endometrial Cancer · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04816682 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Last refreshed: 3 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04816682.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing